Gainers:
1. EyePoint Pharmaceuticals (EYPT) stock rose by a staggering 172.8% to $18.03 during Monday’s regular session. The company’s market cap currently stands at $636.6 million.
2. Alterity Therapeutics (ATHE) stock increased by 122.28% to $3.69. The market value of their outstanding shares is at $15.0 million.
3. Altimmune (ALT) stock rose by 34.98% to $4.82. The market value of their outstanding shares is at $258.9 million.
4. CEL-SCI (CVM) stock increased by 34.3% to $2.78. The company’s market cap stands at $138.9 million.
5. Lucy Scientific Discovery (LSDI) shares rose by 31.68% to $0.28. The company’s market cap stands at $4.8 million.
6. Biomea Fusion (BMEA) shares increased by 30.33% to $21.74. The company’s market cap stands at $776.2 million.
Losers:
1. NexImmune (NEXI) shares fell by 33.7% to $4.01 during Monday’s regular session. The market value of their outstanding shares is at $4.2 million.
2. BioAtla (BCAB) stock fell by 20.63% to $1.41. The company’s market cap stands at $67.3 million.
3. Vivos Therapeutics (VVOS) shares fell by 20.22% to $15.88. The company’s market cap stands at $21.1 million.
4. Conduit Pharmaceuticals (CDT) stock declined by 18.34% to $4.5. The market value of their outstanding shares is at $327.6 million.
5. OneMedNet (ONMD) shares fell by 15.47% to $3.5. The company’s market cap stands at $112.9 million.
6. ASLAN Pharma (ASLN) stock fell by 15.08% to $0.54. The company’s market cap stands at $8.9 million.
This article highlights the gainers and losers in the stock market on Monday. EyePoint Pharmaceuticals experienced a significant surge, with their stock rising by 172.8%. This impressive increase led to the company’s market cap reaching $636.6 million. Alterity Therapeutics also witnessed a substantial rise in their stock, increasing by 122.28%. Meanwhile, Altimmune saw a rise of 34.98% in their stock.
On the other hand, NexImmune faced a significant decline of 33.7% in their stock. This decrease led to their market value of outstanding shares dropping to $4.2 million. BioAtla also experienced a decline of 20.63% in their stock, resulting in a market cap of $67.3 million.
It is important to note that these fluctuations in stock prices can be influenced by various factors, including market conditions, company performance, and investor sentiment. Investors should carefully analyze the relevant information and consult with financial advisors before making any investment decisions.
This article was generated by Benzinga’s automated content engine and reviewed by an editor. Benzinga does not provide investment advice, and all rights are reserved.
Sources:
– Benzinga.com
